Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency - 2013/02/05
On January 10th 2013, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London.
VitamFero signs agreement with Merial to develop new production animal antiparasitic vaccines - 2013/01/21
VitamFero has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal parasites.
Progeria: Discovery of a molecular mechanism that protects neurons from premature aging - 2012/06/21
Xavier Nissan’s team I-Stem, at the Institute for Stem Cell Research in the Treatment and Study of Monogenic Diseases (ISTEM-EUVE U861/Inserm/AFM), under the direction of Dr. Marc Peschanski, has discovered a molecular mechanism in progeria (also called Hutchinson-Gilford progeria syndrome) that protects neural cells from the disease’s characteristic premature aging. Their work, carried out in collaboration with Nicolas Lévy’s team at the La Timone Faculty of Medicine, Université de la (...)
VitamFero increases its assets with excellent results for two of its veterinary candidates - 2012/10/17
VitamFero, a biotechnology firm in the Genopole® cluster with a secondary facility in Tours, develops novel veterinary vaccines to prevent certain parasitic diseases. It announces the filing of two new patent applications protecting the highly favourable results for its vaccine candidates VFOne-273 and VFOct-291 that target ruminant neosporosis and cryptosporidiosis, respectively.
Genethon receives the 2012 Prix Galien France - 2012/10/05
The 43rd Prix Galien France today recognized Genethon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy and gene therapy.” Created in 1990 by a patient association, the AFM-Téléthon, and 90% financed by donations from the French Téléthon, Genethon is dedicated to the development of gene therapy treatments for rare diseases - from their discovery through production and through their (...)
GLOBAL BIOENERGIES receives the “most innovative European biotech SME” EuropaBio award
Global Bioenergies, the industrial biology company developing sustainable routes to light olefins, has been selected by EuropaBio, the organization representing more than 1800 European companies, to receive the “most innovative European biotech SME” award.
A SHANGHAI PHYSIOTHERAPY CENTER CHOOSES LOCOMETRIX - 2012/09/13
The Genopole®-accredited company Centaure Metrix, specialist in the diagnosis and treatment of gait disorders, recently installed their Locometrix® gait diagnostics and therapy system in the Shanghai Sunny Rehabilitation Center, a physical therapy leader in China. The center receives numerous patients with neurological or orthopedic disorders (hemiplegic patients, accident survivors, elderly patients with high falling risks, etc.). Its staff was looking for gait analysis material and active (...)